PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors

CONCLUSION: PD-L1 expression on CTCs is a promising biomarker in patients with NSCLC treated with ICIs. Further validation as predictive biomarker is needed.PMID:33849808 | DOI:10.1016/j.cllc.2021.03.005
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research